| Entry |
|
|---|
| Name |
Gefitinib (JAN/USAN/INN);
Iressa (TN) |
|---|
| Product |
|
|---|
| Formula |
C22H24ClFN4O3
|
|---|
| Exact mass |
446.1521
|
|---|
| Mol weight |
446.9024
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
|
|---|
| Remark |
| Therapeutic category: | 4291 |
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Disease |
Non-small cell lung cancer (EGFR mutation positive) [DS: H00014] |
|---|
| Target |
|
|---|
| Network |
| N10005 | First/second-generation tyrosine kinase inhibitor to EGFR mutation |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinase inhibitors |
|
|---|
| Other map |
| map01521 | EGFR tyrosine kinase inhibitor resistance |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
L01EB01 Gefitinib
D01977 Gefitinib (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Gefitinib
D01977 Gefitinib (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D01977 Gefitinib (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR* [HSA_VAR:1956v2]
D01977 Gefitinib (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01977
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01977
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01977
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01977
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D01977
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 31
1 C8x C 14.9262 -11.3780
2 N5x N 14.9262 -12.7769
3 C8y C 16.1377 -13.4764
4 C8y C 17.3492 -12.7769
5 C8y C 17.3492 -11.3780
6 N5x N 16.1377 -10.6786
7 C8x C 18.5607 -13.4764
8 C8y C 19.7722 -12.7769
9 C8y C 19.7722 -11.3780
10 C8x C 18.5607 -10.6786
11 N1b N 16.1377 -14.8754
12 O2a O 20.9864 -10.6770
13 C1a C 22.1998 -11.3776
14 O2a O 20.9864 -13.4779
15 C1b C 22.1998 -12.7773
16 C1b C 23.4120 -13.4764
17 C1b C 24.6236 -12.7769
18 N1y N 25.8350 -13.4764
19 C8y C 17.3499 -15.5752
20 C8x C 17.3499 -16.9737
21 C8y C 18.5614 -17.6732
22 C8y C 19.7728 -16.9737
23 C8x C 19.7728 -15.5752
24 C8x C 18.5614 -14.8758
25 X F 20.9866 -17.6744
26 X Cl 18.5614 -19.0779
27 C1x C 25.8349 -14.8826
28 C1x C 27.0470 -15.5825
29 O2x O 28.2592 -14.8827
30 C1x C 28.2593 -13.4765
31 C1x C 27.0472 -12.7766
BOND 34
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 1
5 5 6 1
6 1 6 2
7 4 7 2
8 7 8 1
9 8 9 2
10 9 10 1
11 5 10 2
12 3 11 1
13 9 12 1
14 12 13 1
15 8 14 1
16 14 15 1
17 15 16 1
18 16 17 1
19 17 18 1
20 11 19 1
21 19 20 2
22 20 21 1
23 21 22 2
24 22 23 1
25 23 24 2
26 19 24 1
27 22 25 1
28 21 26 1
29 18 27 1
30 27 28 1
31 28 29 1
32 29 30 1
33 30 31 1
34 18 31 1
|
|---|
